JAK1 and juvenile idiopathic arthritis: Baricitinib is an oral small-molecule inhibitor of JAK1/2 signaling which is approved for the management of RA, juvenile idiopathic arthritis (JIA), atopic dermatitis (AD), AA, and coronavirus disease 2019 (COVID-19).